Monoclonal Antibodies to Adhesion Molecules in Bone Marrow and Organ Transplantation
A number of adhesion molecules have been characterized in the recent past. Molecules belonging to three families, i.e. selectins, integrins and members of the immunoglobulin superfamily mediate major events of immune reactions.1,2 These events include migration of naïve cells to lymphoid organs (homing), adhesion of T cells to antigen-presenting cells, adhesion between effector helper or cytotoxic T cells and B cells or target cells respectively, migration of lymphocytes (as well as monocytes and granulocytes) from the blood stream to sites of immune reaction. T-cell activation and migration are obvious key phenomena in the process of graft rejection and graft versus host disease (GVHD). Adhesion molecules therefore represent logical targets for immunointervention aim at preventing graft rejection. In this chapter, we review the current experimental and clinical data on the in vivo use of anti-adhesion molecule antibodies in the field of transplantation.
KeywordsGraft Rejection Leukocyte Adhesion Deficiency Corneal Allograft Engraftment Rate Prevent Graft Rejection
Unable to display preview. Download preview PDF.
- 12.Fischer A, Lisowska-Grospierre B, Anderson DC et al. The leukocyte adhesion deficiency. Immunodef Rev 1988; 2: 39–54.Google Scholar
- 14.Thomas C, Le Deist F, Friedrich W et al. Bone marrow transplantation for the treatment of children with leukocyte adhesion deficiency. A revue of 14 cases. Submitted.Google Scholar
- 15.Kohl S, Loo Ls, Schmalstieg FS et al. The genetic deficiency of leukocyte surface glycoproteins Mac-1, LFA-1, p150,95 in humans is associated with defective antibody-dependent cellular cytotoxicity and defective protection against herpes simplex virus infection in vivo. J Immunol 1986; 177: 1688–1693.Google Scholar
- 16.Muller KE, Rutten UPMG, Becker CK et al. Skin transplantations in β2-integrin deficient cattle.Google Scholar
- 24.Cavazzaana-Calvo M, Sarnacki S, Haddad E et al. Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody. Submitted.Google Scholar
- 36.He YG, Mellon J, Apte R et al. Effect of LFA-1 and ICAM-1 antibody treatment on murine corneal allograft survival. Invest Ophtalmol Vis Sci 1994; 35: 3218–3225Google Scholar
- 41.Fischer A, Blanche S, Veber F et al. Prevention of graft failure by an anti-LFA-1 monoclonal antibody in HLA mismatched bone marrow transplantation. Lancet 1986; 2: 1068–1071.Google Scholar
- 43.Fischer A, Friedrich W, Fasth A et al. Reduction of graft failure by a monoclonal antibody (anti-LFA-1, CD11a) after HLA-non identical bone marrow transplantation in children with immunodeficiencies, osteopetrosis and Fanconi’s anemia. Blood 1991; 2: 249–256.Google Scholar
- 44.Jabado N, Le Deist F, De Graaf Meiders B et al. Combined use of two monoclonal antibodies (anti-LFA-1 and anti-CD2) to prevent graft rejection in recipients of T-depleted marrow from genetically HLA-non identical donors in children with inherited disorders. Submitted.Google Scholar
- 45.Cavazzana-Calvo M, Bordigoni P, Michel G, Baruchel A et al. Partially incompatible marrow transplantation therapy for high risk acute lymphoblastic leukemia in children: Analysis of prevention of graft rejection by anti-LFA-1 and anti-CD2 antibodies. A SFGM study. Submitted.Google Scholar
- 47.Marawinchi D, Mawas C, Stoppa AM et al. Anti-LFA-1 monoclonal antibody for the prevention of graft rejection after T-cell depleted HLA-matched bone marrow transplantation for leukemia in adults. Bone Marrow Transplant 1989; 4: 147.Google Scholar